Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
News for 60 Degrees Pharmaceuticals, Inc. (warrants: SXTPW) centers on its activities as a pharmaceutical company focused on developing and commercializing medicines for vector-borne diseases. Company announcements repeatedly highlight work in malaria prevention through its FDA-approved product ARAKODA (tafenoquine), as well as clinical research programs in babesiosis, an emerging tick-borne illness for which no FDA-approved treatment currently exists.
Investors and observers following SXTPW-related news will see updates on clinical trial milestones, including the B-FREE Chronic Babesiosis Study (NCT06656351) and other tafenoquine studies in hospitalized and relapsing babesiosis patients. Releases describe study designs, enrollment progress, and early findings such as Babesia detection rates in chronic fatigue cohorts or parasite status in individual patients completing treatment regimens.
Company news also covers commercial and marketing developments for ARAKODA, such as expansion of inside sales teams, partnerships with platforms like GoodRx to broaden offer visibility, and digital marketing campaigns aimed at prescribers. Financial updates, including quarterly results and commentary on product demand trends, appear alongside these operational highlights.
Regulatory and capital markets items form another important news category. Examples include announcements of reverse stock splits intended to support continued Nasdaq listing, at-the-market sales agreements for common stock, and participation in investor conferences where management presents the company’s vector-borne disease strategy.
For readers tracking SXTPW, the news stream offers a view into how 60 Degrees Pharmaceuticals advances its malaria franchise, builds a babesiosis clinical program, manages its Nasdaq-listed securities, and collaborates with academic and research institutions in the U.S. and Australia. Bookmark this page to follow ongoing disclosures about trials, regulatory interactions, financing transactions, and other material events tied to the company’s warrants and underlying common stock.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) partnered with GoodRx (Nasdaq: GDRX) to offer eligible patients savings of up to 30% on ARAKODA® (tafenoquine), effective Feb 2, 2026. The program expands access at more than 70,000 pharmacies nationwide and may include home delivery where available.
This collaboration aims to lower out-of-pocket costs and broaden the company’s marketing reach for its FDA-approved, once-weekly malaria prevention therapy for travelers to endemic regions.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) exercised its option with Florida State University to negotiate an exclusive license for large-scale purification of castanospermine from Castanospermum australe seeds.
The company completed safety testing, developed prototype oral capsules, and is ready to commence a regulatory process to seek U.S. market access as a botanical non-prescription product. Prior clinical history tied to celgosivir involved more than 500 patients, which the company cites when noting human safety at achievable doses.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for malaria prevention among international travelers. ARAKODA is described as the only FDA-approved, broad-spectrum, once-weekly prescription malaria prevention on the U.S. market. Runway Health will offer physician-led online consultations and, if prescribed, seamless home delivery that arrives before departure. The partnership commences April 2, 2026 and lets eligible users match travel itineraries with personalized treatment plans designed by a U.S.-licensed healthcare provider.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) will effect a one-for-four (1:4) reverse stock split of its common stock, effective January 20, 2026 at 12:01 AM ET, before market open. The company said the reverse split is intended to bring SXTP into compliance with Nasdaq's minimum bid price requirement. The reverse split will change the CUSIP to 83006G500, reduce outstanding shares from approximately 5,148,767 to approximately 1,287,192, and adjust all outstanding options, warrants, restricted stock awards and equity plan share counts. Par value and authorized share totals remain unchanged. Fractional shares will be rounded up to the next whole share.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that a peer-reviewed, sponsored study at North Carolina State found Babesia infection in 24% of 50 patients presenting with chronic fatigue. The Company said these results support the theory that Babesia may prolong recovery in chronic fatigue and reinforce continuation of the B-FREE Chronic Babesiosis Study (NCT06656351), which is evaluating a 90-day ARAKODA (tafenoquine) regimen for resolution of severe fatigue. The B-Free study is enrolling at the Icahn School of Medicine at Mount Sinai in New York. The release notes that tafenoquine is approved in the U.S. for malaria prophylaxis as ARAKODA but is not proven or FDA-approved to treat or prevent babesiosis.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a planned expansion of sales and marketing for ARAKODA after a 6-month commercial pilot showed increasing product sales among prescribers. Plans for 2026 include doubling inside sales representatives, a new GoodRx partnership to broaden point-of-sale visibility, and an enhanced digital "surround sound" marketing campaign to boost prescriber awareness and engagement.
Separately, the company will add at least two babesiosis clinical sites for ongoing randomized and expanded-access studies following FDA feedback on its Breakthrough Therapy designation request; FDA declined the request but acknowledged babesiosis as serious and suggested resubmission with controlled-trial data. Tafenoquine (ARAKODA) remains approved for malaria prophylaxis and is not approved for babesiosis treatment.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) opened the central site at Mount Sinai Icahn School of Medicine to enroll patients in the B-FREE Chronic Babesiosis Study on Nov 21, 2025.
The Phase 2 open-label study (NCT06656351) will evaluate an ARAKODA® (tafenoquine) regimen over 90 days for resolution of severe fatigue and parasite eradication, will run ~12 months, and plans to enroll up to 100 patients. Internal estimates put the U.S. unmet need between 4,400 and 190,000 cases annually; a study aim is to confirm Babesia infection using validated molecular tests to refine market size. Tafenoquine is approved for malaria prophylaxis as ARAKODA® but is not approved or proven for babesiosis treatment.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2025 results for the quarter ended September 30, 2025. Net product revenue rose 223% YoY to $438,000 and ARAKODA pharmacy deliveries increased 14% to 1,505 boxes. The company recorded a gross loss of ~$100,000 versus a $24,000 gross profit a year earlier due to a one-time inventory write-off tied to short shelf-life validation lots. Operating expenses were ~$2.32 million, driven by an additional $367,000 in advertising and sales promotion. Net loss attributable to common shareholders was approximately $2.44 million or ($0.66) per share. New four-year shelf-life lots are expected to enter the supply chain in early Q1 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that the first patient completing its expanded access study of ARAKODA® (tafenoquine) for relapsing babesiosis tested negative for Babesia by both a Mayo Clinic RT-PCR and an FDA-licensed RNA amplification assay that is described as at least 100x more sensitive than standard RT-PCR.
On October 3, 2025 the company submitted a Breakthrough Therapy request to FDA and plans a Type B meeting in early 2026 to discuss requirements for a supplementary NDA; remaining patients are expected to finish between January and October 2026 and clinical data are expected in second half of 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) named its chronic babesiosis Phase 2 trial the B-FREE Chronic Babesiosis Study (NCT06656351). The open-label study will begin in early November and run for approximately 12 months, testing a 90-day ARAKODA® (tafenoquine) regimen for resolution of severe fatigue and parasite eradication in chronic babesiosis. No FDA-approved or society-recommended treatment for chronic babesiosis currently exists. The company donated $5,000 split between Global Lyme Alliance and ILADEF after a patient-driven naming contest.